AVN-211 (CD-008-0173) is a drug which acts as a highly selective 5-HT6 receptor antagonist and is under development by Avineuro Pharmaceuticals for the treatment of schizophrenia.[1][2][3] In early 2011, it successfully completed phase IIa clinical trials,[1][4] with benefits on positive symptoms and some procognitive effects observed,[5] and in mid 2013, phase IIb clinical trials for schizophrenia began.[6] Avineuro Pharmaceuticals also expressed intention to start clinical trials of AVN-211 for Alzheimer's disease in 2015.[6][7][needs update]
Clinical data | |
---|---|
Other names | CD-008-0173 |
Identifiers | |
| |
CAS Number |
|
ChemSpider |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C15H15N3O2S2 |
Molar mass | 333.42 g·mol−1 |
3D model (JSmol) |
|
| |
|